v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Purchase Price Allocation (Details) - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 14, 2023
Business Combination [Line Items]        
Goodwill [1] $ 71,264 $ 68,527 $ 67,783  
Seagen [Member]        
Business Combination [Line Items]        
Working capital, excluding inventories [2]       $ 621
Inventories [3]       3,273
Property, plant and equipment       280
Other noncurrent assets       59
Net income tax accounts [4]       (4,779)
Other noncurrent liabilities       (187)
Total identifiable net assets       27,086
Goodwill       17,148
Net assets acquired/total consideration transferred       44,234
Seagen [Member] | IPR&D [Member]        
Business Combination [Line Items]        
Intangible assets       19,900
Seagen [Member] | Developed Technology Rights and Other Intangible Assets [Member]        
Business Combination [Line Items]        
Intangible assets [5]       $ 7,920
[1] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2025 (see Note 17A), our goodwill was reallocated among impacted reporting units. We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
[2] Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.
[3] Comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
[4] Included primarily in Noncurrent deferred tax liabilities.
[5] Comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.